Protalix Therapeutics Inc.'s finish of the pivotal Phase III trial with prGCD, a plant cell-expressed recombinant form of glucocerebrosidase for Gaucher's disease, put hot breath on the neck of Genzyme Corp., still grappling with problems brought about by a virus discovered in one of the reactors used to make its therapy. Read More
